SPINA, Edoardo
 Distribuzione geografica
Continente #
NA - Nord America 7216
EU - Europa 7204
AS - Asia 1099
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 9
AF - Africa 6
OC - Oceania 6
Totale 15549
Nazione #
US - Stati Uniti d'America 7190
IE - Irlanda 2332
SE - Svezia 1676
CN - Cina 1048
UA - Ucraina 860
IT - Italia 702
DE - Germania 632
FI - Finlandia 364
GB - Regno Unito 231
PL - Polonia 157
FR - Francia 80
BE - Belgio 72
RU - Federazione Russa 35
NL - Olanda 30
CA - Canada 23
VN - Vietnam 18
TR - Turchia 11
CL - Cile 9
CH - Svizzera 7
IN - India 7
AU - Australia 6
ES - Italia 6
EU - Europa 6
IR - Iran 5
AL - Albania 4
RO - Romania 4
MX - Messico 3
A1 - ???statistics.table.value.countryCode.A1??? 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
ID - Indonesia 2
IL - Israele 2
JP - Giappone 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LT - Lituania 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 15549
Città #
Dublin 2332
Jacksonville 1747
Chandler 1522
Nyköping 751
Beijing 516
Princeton 400
Cambridge 361
Dearborn 358
Des Moines 277
Medford 247
Boardman 209
Ann Arbor 194
Messina 166
Warsaw 156
Wilmington 123
Lancaster 93
Houston 83
Woodbridge 77
Jinan 74
Brussels 72
San Mateo 64
Shenyang 64
Bremen 62
Nanjing 47
Hebei 34
Ashburn 32
Haikou 32
Hangzhou 32
Norwalk 29
Tianjin 29
Ningbo 26
Taizhou 26
Zhengzhou 26
Seattle 20
Catania 19
Dong Ket 18
Helsinki 18
Rome 18
Guangzhou 17
Ottawa 17
Changsha 16
Milan 16
Nanchang 16
Fuzhou 15
Jiaxing 15
Saint Petersburg 14
Falls Church 12
Auburn Hills 10
Taiyuan 10
Clearwater 9
Kastamonu 8
Palermo 8
Fiumefreddo Di Sicilia 7
Strasbourg 7
Urbino 7
Lanzhou 6
Los Angeles 6
Paris 6
Torino 6
Bologna 5
Fairfield 5
Florence 5
Genova 5
Napoli 5
Redmond 5
Riva 5
Verona 5
Augusta 4
Enschede 4
Hanover 4
Mascali 4
Massa 4
New York 4
Novokuznetsk 4
Philadelphia 4
Redwood City 4
Xiangfen 4
Zurich 4
Ardabil 3
Caltagirone 3
Cusano Milanino 3
Hefei 3
Manduria 3
Mineo 3
Monza 3
Salerno 3
Soverato 3
Toronto 3
Töreboda 3
Adliswil 2
Amsterdam 2
Bari 2
Bratislava 2
Brescia 2
Brooklyn 2
Buffalo 2
Cagliari 2
Canberra 2
Caserta 2
Castelnuovo Rangone 2
Totale 10721
Nome #
Cutis verticis gyrata primitiva o pachidermia verticis gyrata: contributo clinico-istologico 292
Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study 112
Adverse Drug Reactions in Hospitalized patients: results of the FORWARD (Facilitation of reporting in hospital Ward) study. 105
Efficacia di un trattamento aggiuntivo con olanzapina nel disturbo ossessivo-compulsivo resistente agli SSRI 103
Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study 95
Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder 94
Aripiprazolo in bambini con ADHD in comorbidità con Disturbo da Tic 89
Augmentation con Lamotrigina in pazienti con schizofrenia resistente in trattamento con Clozapina 87
Uso dell’Aripiprazolo in bambini con Multiple-complex Developmental Disorder (McDD). 86
Confronto Teofillina-Doxofillina nella risoluzione del broncospasmo 83
A molecular pathway analysis informs the genetic background at risk for schizophrenia. 82
Interazione farmacocinetica tra mirtazapina e clozapina in pazienti schizofrenici. 79
Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report 77
PATTERN PRESCRITTIVO DI FARMACI ANTIEPILETTICI NELL'ANZIANO: STUDIO DI POPOLAZIONE IN UN'AREA DEL SUD ITALIA NEGLI ANNI 2004-2007 76
Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients: Results from a 60-days open-label study 76
Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder 73
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population 71
Antidepressant use in the elderly: The role of pharmacodynamics and pharmacokinetics in drug safety 68
No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population 65
Aripiprazole in Children with Multiple-complex Developmental Disorder (McDD): a case series. 65
Aripiprazole in Children with Multiple-complex Developmental Disorder (McDD): a case series. 65
“Effect of valproic acid on plasma concentrations of olanzapine in patients with psychiatric disorders” 64
PARKINSONISMO ED INIBITORI SELETTIVI DEL REUPTAKE DELLA SEROTONINA 64
ABCB1 polymorphisms influence steady state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. 64
Acute Cerebellar Ataxia Following Meningococcal Group C Conjugate Vaccination 64
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. 64
Generic Olanzapine Substitution in Patients with Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching 63
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study 63
Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? 62
“Newer and older antiepileptic drug in southern Italy: a population based study during the years 2003-2005” 61
Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications 61
Antidepressant effect of hypericum perforatum extract on behaviour and neurogenesis in chronic corticosterone-treated mice. 61
Ototoxic adverse drug reactions: A disproportionality analysis using the Italian spontaneous reporting database 61
INFLUENCE OF CYP2C9 POLYMORPHISM IN LUNG CANCER SUSCEPTIBILITY 60
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. XVII Congresso Nazionale della Società Italiana di Neuropsicofarmacologia, Cagliari 22-25 Settembre 2010, p. 47. 60
Aripiprazole enhances the antidepressant effect of fluoxetine in mice. 60
Impiego clinico del Risperidone in età evolutiva: variazioni farmacocinetiche e cliniche 59
Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics 59
Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011 58
Off-label use of second-generation antipsychotics 57
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 57
Age-related changes in pharmacodynamics: focus on drug acting on cetral nervous and cardiovascular systems 57
Evaluation of putative cytotoxic activity of crude extracts from Onopordum acanthium leaves and Spartium junceum flowers against the U-373 glioblastoma cell line. 57
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. 57
The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia 56
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone 56
AN ENDOCRINOLOGIC STUDY OF PATIENTS WITH PRIMARY-CUTIS-VERTICIS GYRATA 56
A pharmacokinetic-pharmacodynamic method for predicting warfarin maintenance dose: preliminary results 56
"Valproic acid-amitriptyline interaction in man 56
Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs. 56
Impiego del Risperidone nel disturbo autistico: valutazioni farmacocinetiche e cliniche 55
Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice 55
Aripiprazole augmentation of serotinin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study 55
“Augmentation con Duloxetina vs. placebo in un campione di schizofrenici partial responders in trattamento stabilizzato con antipsicotici atipici”. 54
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olazapine and risperidone I patients with psychotic disorders 54
Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study 54
Safety and tolerability of psychotropic medications in childhood: preliminary data of a pharmacovigilance study 54
n-3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell (BAFF) transgenic mice 53
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity 53
5-HT2A and 5-HT2C receptor polymorphisms and psychotic symptoms in Alzheimer's disease 53
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 53
Aripiprazole enhances the antidepressat effect of fluoxetine in mice. 53
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 53
Pharmacogenomics in Psychiatry 53
Effetto di un trattamento con risperidone o olanzapina sui livelli serici di prolattina in bambini e adolescenti con patologie psichiatriche. 52
Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. 52
Short-term memory loss associated with rosuvastatin. 52
Systemic cardiorespiratory effects induced by doxofylline 52
6-Mer Hyaluronan Oligosaccharides ModulateNeuroinflammation and a-Synuclein Expression inNeuron-Like SH-SY5Y Cells 52
Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents 52
Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease 51
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia 51
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. 51
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 51
Interactions between antiepileptics and second generation antipsychotics 51
Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study. 51
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder 50
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders 50
Metabolic drug interactions with newer antipsychotics: a comparative review. 50
Profilo di tollerabilità degli antipsicotici atipici e degli inibitori selettivi della ricaptazione della serotonina in età evolutiva. 50
ADJUNCTIVE FLUOXETINE IN THE TREATMENT OF NEGATIVE SYMPTOMS IN CHRONIC-SCHIZOPHRENIC PATIENTS 50
PHARMACOKINETIC INTERACTIONS BETWEEN TRICYCLIC ANTIDEPRESSANTS AND OTHER PSYCHOTROPIC-DRUGS IN DEPRESSED-PATIENTS 50
Effect of valpromide on the pharmacokinetics of Carbamazepine-10,11-epoxide 50
ANTITHETIC ACTION OF HYALURONAN 6-MER IN UNDIFFERENTIATED AND DIFFERENTIATED SH-SY5Y CELLS 50
Impiego clinico dell'olanzapina in età evolutiva 49
Prescribing pattern of antiepileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-2007 49
Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. 49
Fase prodromica della schizofrenia: prospettive diagnostiche ed opportunità terapeutiche 49
ECG parameters in children and adolescents treated with aripiprazole and risperidone 49
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study 48
Livelli serici di prolattina in corso di trattamento con risperidone o olanzapina in bambini ed adolescenti con patologie psichiatriche. 48
Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. 48
Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies 48
Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during 1999-2002 years 47
Tolerability of antipsychotics in children and adolescents: a prospective study. 47
Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. 47
Effect of adjunctive duloxetine treatment on the plasma concentrations of clozapine, olanzapine and risperidone in patients with psychotic disorders 47
Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. 47
Livelli serici di prolattina in corso di trattamento con risperidone o olanzapina in bambini ed adolescenti con patologie psichiatriche. 47
Effect of valproate on plasma concentrations of olanzapine in patients with psychotic disorders , July, 2009, MP 110.. 47
Totale 6208
Categoria #
all - tutte 33880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33880


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201827 0000 00 00 00027
2018/2019538 1217442 29340 5722 5171514
2019/20202891 45221412192 16378 365312 5631454733
2020/20212408 28222545138 156299 56243 56338133140
2021/20222228 272253178 5023 133114 83446293725
2022/20236158 509412218480 521543 57353 2855371730
Totale 15861